Ten years of TRALI mitigation: measuring our progress.

摘要: BACKGROUND Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-associated mortality for which multiple mitigation strategies have been implemented over the past decade. However, product-specific TRALI rates not reported longitudinally and may help refine additional strategies. STUDY DESIGN AND METHODS This retrospective multicenter study included analysis from 2007 through 2017. Numerators definite or probable reports five blood centers serving nine states in United States. Denominators were components distributed participating centers. Rates calculated as per 100,000 (p < 0.05 significant). RESULTS One hundred four cases 10,012,707 (TRALI rate 1.04 components). The was 2.25 female versus 1.08 male donated (p < .001). declined 2.88 to 0.60 From 2013, there significantly higher associated with plasma (33.85 vs. 1.59; p < 0.001) RBCs (1.97 1.15; p = 0.03). 2014 2017, after implementation strategies, only female-donated plateletpheresis continued be observed (2.98 0.75; 0.04). CONCLUSION Although substantially decreased secondary decade, residual risk remains, particularly products. Additional tools that further mitigate incidence include use buffy coat pooled platelets suspended donor platelet additive solution due lower amounts plasma.